Safety and immunogenicity of the Towne strain cytomegalovirus vaccine

Pediatric Infectious Disease Journal

Volumn 17, Issue 3, 1998, Pages 200-206

  Adler, Stuart P ^a   Hempfling, Sue H ^a   Starr, Stuart E ^b   Plotkin, Stanley A ^c   Riddell, Stanley ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Pasteur Merieux Connaught ^*  (France)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytomegalovirus; Cytomegalovirus vaccine; Immunogenicity; Safety; Towne vaccine

Indexed keywords

CD8 ANTIGEN; CYTOMEGALOVIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL; VACCINATION; VIRUS IMMUNITY; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0031920697     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199803000-00006     Document Type: Article

References (26)

1. Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326:663-73.
2. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991;114:525-31.
3. Balfour HH Jr, Welo PK, Sachs GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc 1985;17:81-3.
4. Glazer JP, Friedman HM, Grossman RA, et al. Live cytomegalovirus vaccination of renal transplant candidates: a preliminary trial. Ann Intern Med 1979;91:676-83.
5. Plotkin SA, Farquhar J, Hornberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 1976;134:470-5.
6. Plotkin SA, Starr SE, Friedman HM, Gönczöl E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989;159:860-5.
7. Plotkin SA, Huang ES. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 1985;152: 395-7.
8. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by a primary cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
9. Adler SP. Molecular epidemiology of cytomegalovirus: viral transmission among children attending a day-care center, their parents, and caretakers. J Pediatr 1988;112:366-72.
10. Adler SP, McVoy M, Biro VG, Britt WJ, Hider P, Marshall D. The detection of antibody against cytomegalovirus using latex agglutination. J Clin Microbiol 1985;22:68-70.
11. Adler SP, McVoy M. Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for and effect resulting from strain heterogeneity. J Clin Microbiol 1986; 24:870-2.
12. Gönczöl E, Furlini G, Ianacone J, Plotkin SA. A rapid microneutralization assay for cytomegalovirus. J Virol Methods 1986;14:37-41.
13. Starr SE, Dalton B, Garrabrant T, Paucker K, Plotkin SA. Lymphocyte blastogenesis and interferon production in adult human leukocyte cultures stimulated with CMV antigens. Infect Immun 1980;30:17-22.
14. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991;146: 2795-804.
15. Wills MR, Carmichael AJ, Mynard K, Jin X, et al. The human cytotoxic T-Lymphocyte (CTL) responses to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
16. Borysiewicz LK, Hickling JK, Graham S, et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 1988;168:919-31.
17. McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-10.
18. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
19. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 1993;67:3461-9.
20. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.
21. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-80.
22. Quinnan GV Jr, Kirmani N, Esber E, et al. HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. J Immunol 1981;126:2036-41.
23. Quinnan GV Jr, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13.
24. Adler SP. Cytomegalovirus and child day-care: risk factors for maternal infection. Pediatr Infect Dis J 1991;10:590-4.
25. Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to CMV glycoprotein B occur following both natural infection and immunization with human cytomegaloviral vaccines. J Infect Dis 1996;174:387-92.
26. Wang JB, Adler SP. Salivary antibodies to cytomegalovirus (CMV) glycoprotein B accurately predict CMV infections among preschool children. J Clin Microbiol 1996;34: 2632-43.